Connection

LAWRENCE DONEHOWER to Mice, Transgenic

This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Mice, Transgenic.
Connection Strength

0.750
  1. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses. Mol Cancer Res. 2012 Jun; 10(6):845-55.
    View in: PubMed
    Score: 0.067
  2. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer. 2009 11; 9(11):831-41.
    View in: PubMed
    Score: 0.056
  3. Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging. Mech Ageing Dev. 2009 Apr; 130(4):262-71.
    View in: PubMed
    Score: 0.054
  4. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res. 2005 Aug 25; 576(1-2):4-21.
    View in: PubMed
    Score: 0.042
  5. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene. 2003 Oct 30; 22(49):7831-7.
    View in: PubMed
    Score: 0.037
  6. Functional analysis of tumor suppressor genes in mice. Methods Mol Biol. 2003; 223:283-314.
    View in: PubMed
    Score: 0.035
  7. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol. 2002 Feb; 22(4):1094-105.
    View in: PubMed
    Score: 0.033
  8. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002 Jan 03; 415(6867):45-53.
    View in: PubMed
    Score: 0.033
  9. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol. 2001; 29 Suppl:147-54.
    View in: PubMed
    Score: 0.031
  10. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ. 1999 Apr; 10(4):213-22.
    View in: PubMed
    Score: 0.027
  11. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ. 1997 Aug; 8(8):829-38.
    View in: PubMed
    Score: 0.024
  12. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol. 1996 Oct; 7(5):269-78.
    View in: PubMed
    Score: 0.023
  13. The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res. 1996; 395:1-11.
    View in: PubMed
    Score: 0.022
  14. Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma. Genes Chromosomes Cancer. 2015 Dec; 54(12):796-808.
    View in: PubMed
    Score: 0.021
  15. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 1995 Apr 01; 9(7):882-95.
    View in: PubMed
    Score: 0.020
  16. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet. 1995 Mar; 9(3):305-11.
    View in: PubMed
    Score: 0.020
  17. Notch activation as a driver of osteogenic sarcoma. Cancer Cell. 2014 Sep 08; 26(3):390-401.
    View in: PubMed
    Score: 0.020
  18. Transgenic animals in toxicology. Fundam Appl Toxicol. 1994 Jan; 22(1):8-19.
    View in: PubMed
    Score: 0.019
  19. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19; 356(6366):215-21.
    View in: PubMed
    Score: 0.017
  20. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat. 2011 Nov; 130(2):399-408.
    View in: PubMed
    Score: 0.015
  21. DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle. 2006 Sep; 5(17):2005-11.
    View in: PubMed
    Score: 0.011
  22. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003 Sep; 23(17):6159-73.
    View in: PubMed
    Score: 0.009
  23. Cancer prevention studies in p53-deficient mice. Toxicol Pathol. 2001 Jan-Feb; 29(1):137-41.
    View in: PubMed
    Score: 0.008
  24. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem. 2000 Oct 20; 275(42):32649-57.
    View in: PubMed
    Score: 0.008
  25. Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. Mol Carcinog. 2000 Oct; 29(2):67-75.
    View in: PubMed
    Score: 0.007
  26. Absence of p53: no effect in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol. 2000 Sep; 165(1):184-90.
    View in: PubMed
    Score: 0.007
  27. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000 Jun 15; 14(12):1448-59.
    View in: PubMed
    Score: 0.007
  28. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination. Cancer Res. 2000 Jun 01; 60(11):2831-5.
    View in: PubMed
    Score: 0.007
  29. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15608-12.
    View in: PubMed
    Score: 0.007
  30. Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice. Cell Growth Differ. 1997 Feb; 8(2):121-31.
    View in: PubMed
    Score: 0.006
  31. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 1996 Oct 01; 56(19):4413-23.
    View in: PubMed
    Score: 0.006
  32. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol. 1996 Jul; 16(7):3765-72.
    View in: PubMed
    Score: 0.006
  33. Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? J Virol. 1996 Apr; 70(4):2095-100.
    View in: PubMed
    Score: 0.005
  34. Transgenic mouse models for tumour-suppressor genes. J Intern Med. 1995 Sep; 238(3):233-8.
    View in: PubMed
    Score: 0.005
  35. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc Natl Acad Sci U S A. 1995 Aug 29; 92(18):8517-21.
    View in: PubMed
    Score: 0.005
  36. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol. 1995 Aug; 15(8):4249-59.
    View in: PubMed
    Score: 0.005
  37. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene. 1995 Jul 06; 11(1):181-90.
    View in: PubMed
    Score: 0.005
  38. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene. 1995 May 04; 10(9):1717-23.
    View in: PubMed
    Score: 0.005
  39. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene. 1994 Dec; 9(12):3731-6.
    View in: PubMed
    Score: 0.005
  40. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene. 1994 Nov; 9(11):3107-12.
    View in: PubMed
    Score: 0.005
  41. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):9075-9.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.